Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 2219 word(s) 2219 2021-09-27 03:41:42 |
2 format correct -13 word(s) 2206 2021-09-28 03:21:36 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Montag, D. Neuroplastin in Neuropsychiatric Diseases. Encyclopedia. Available online: (accessed on 14 June 2024).
Montag D. Neuroplastin in Neuropsychiatric Diseases. Encyclopedia. Available at: Accessed June 14, 2024.
Montag, Dirk. "Neuroplastin in Neuropsychiatric Diseases" Encyclopedia, (accessed June 14, 2024).
Montag, D. (2021, September 27). Neuroplastin in Neuropsychiatric Diseases. In Encyclopedia.
Montag, Dirk. "Neuroplastin in Neuropsychiatric Diseases." Encyclopedia. Web. 27 September, 2021.
Neuroplastin in Neuropsychiatric Diseases

Molecular mechanisms underlying neuropsychiatric and neurodegenerative diseases are insufficiently elucidated. A detailed understanding of these mechanisms may help to further improve medical intervention. Recently, intellectual abilities, creativity, and amnesia have been associated with neuroplastin, a cell recognition glycoprotein of the immunoglobulin superfamily that participates in synapse formation and function and calcium signaling. Data from animal models suggest a role for neuroplastin in pathways affected in neuropsychiatric and neurodegenerative diseases. Neuroplastin loss or disruption of molecular pathways related to neuronal processes has been linked to various neurological diseases, including dementia, schizophrenia, and Alzheimer’s disease

plasma membrane Calcium ATPase PMCA autism schizophrenia Alzheimer’s disease calcium homeostasis synaptopathy 15q24 microdeletion syndrome

1. Introduction

The prevalence of mental disorders, including autism spectrum disorder (ASD) and schizophrenia (SZ) [1][2][3], related to neurodevelopmental deficits and neurodegenerative diseases, is predicted to increase in future decades because of a growing and ageing world population. In addition to its severe effects on cognitive and social communication, its economic burden is a major challenge for patients and for economies at an international level [4][5][6][7]. To understand the pathogenesis of neuropsychiatric disorders, it is important to consider that both genetic and environmental factors can act separately or in combination to play crucial roles in these diseases. Based on genome-wide association studies (GWAS) with large groups of patients, potential mechanisms underlying different psychiatric disorders can be elucidated and directly investigated. As GWAS and next generation sequencing (NGS) have rapidly developed recently, many gene loci have been associated with different neuropsychiatric disorders [8]. For instance, numerous genetic variants have been associated with SZ [9][10][11][12][13] and ASD [14][15][16][17]. Furthermore, a significant genetic correlation exists between ASD and SZ [17][18]. In combination with transgenic mouse models targeting the potential risk genes, the association of different psychiatric disorders has been confirmed for explicit genes such as the SHANK genes [19][20][21][22][23]. Furthermore, gene variants leading to synaptic dysfunction play a critical role as causal factors for these psychiatric disorders [24].
The abnormal expression or function of several proteins can affect synaptic transmission and further impair network activities, such as the excitatory and inhibitory balance, contributing to different neuropsychiatric or neurodegenerative diseases [25][26]. Therefore, numerous efforts have focused on exploring interventions with identified pathogenic mechanisms, although many attempts did not achieve the desired clinical outcome [27][28][29][30][31]. As psychiatric disorders frequently exhibit overlapping symptoms, such as the association of cognitive impairment with ASD and SZ [32], it is essential to understand their underlying cellular mechanisms.
In this review, we will focus on recent studies of the cell recognition molecule neuroplastin (Np) and its gene (Nptn/NPTN) in relation to psychiatric and neurodegenerative diseases (Figure 1). We propose that targeting neuroplastin may make it possible to reverse network dysfunctions and contribute to ameliorating the onset and progression of neuropsychiatric diseases.
Figure 1. Schematic illustration of neuroplastin Np55/65 as a central component related to neuropsychiatric and neurodegenerative diseases as well as in other diseases associated with neuroplastin malfunctions.

2. Neuroplastin in Neurological Diseases

A particular syndrome has not yet been attributed to neuroplastin malfunction. However, the observed functions in mouse models and the expression, structure, and interaction partners of neuroplastin, indicate that the impairment of neuroplastin function in humans may result in deleterious consequences for the nervous system. Here, we will review the evidence for the contribution of neuroplastin to neurological pathologies.

2.1. Schizophrenia (SZ) and Autism Spectrum Disorder (ASD)

SZ and ASD manifest as distinct neurodevelopmental diseases. ASD frequently presents in childhood, whereas SZ manifests later in young adults. For both disorders, a heritable genetic contribution was observed, but explicit monogenetic causes have not been identified. Furthermore, a significant association between ASD and SZ was detected [33]. Strikingly, many gene loci related to synaptic function were identified as contributing to both SZ and ASD, suggesting that pathological malfunctions of synapses or synaptopathies may be causal (for review see: [34]). In addition, these two diseases frequently co-occur with attention deficit hyperactivity (ADHD) and bipolar disorder (BD); this is likely resulting from a developmental synaptopathy [35][36]. Brain images from ASD children have shown increased brain size and weight [37] affecting axons and synaptic density [38], which indicate an acceleration of brain development and more synaptic connections. A lack of adolescent synaptic pruning was observed in ASD patients [39], which may account for the dysfunction of brain circuits in ASD [40].
Unlike ASD, which shows an increase in brain growth in all brain regions except occipital grey matter [41], loss of grey matter in SZ was observed [42]. Excessive synaptic pruning in prefrontal cortical synapses was found in SZ neuropathology [43], which indicated reduced synapses and further impairments of the brain circuitry and cognitive functions [44][45].

2.1.1. Neuroplastin Relation to Schizophrenia

In rat models displaying schizophrenia-like symptoms after injection of the two different psychostimulants methamphetamine (MAP) or phencyclidine (PCP), neuroplastin was significantly up-regulated [46]. MAP is a dopamine transporter inhibitor that causes a positive symptom, clinically similar to paranoid schizophrenia in an acute phase [47]. PCP is an NMDA receptor antagonist, which induces both negative and positive schizophrenia-like symptomatology [48]. Subsequent genetic studies of patients with schizophrenia identified three single-nucleotide polymorphisms (SNPs) in the 5′-upstream region of NPTN that were strongly correlated to schizophrenia [49].
Pre-pulse inhibition (PPI) of the startle response is often considered as a characteristic in the diagnosis of schizophrenia [50]. In Nptn-deficient mice, PPI is severely impaired [51], although this could simply result from the profound hearing deficit of these mice [52], rather than processing deficits. Nevertheless, the significant reduction in paired-pulse facilitation in the auditory cortex of Nptn-deficient mice suggests altered cortical synaptic transmission [52]. In addition, the PPI deficit in heterozygous Nptn-deficient mice [51] points to potential central alterations as contributors to the phenotype. As detailed above, the neuroplastin interaction partners AMPA receptor subunit GluA1 and TRAF6 have also been associated with schizophrenia.

2.1.2. Autism Spectrum Disorder (ASD)

Some patients suffering from the heterogeneous 15q24 microdeletion syndrome display ASD and attention deficit hyperactivity disorder (ADHD), in addition to various other deficits [53][54]. NPTN is located at cytogenetic band 15q24.1 and it is deleted or duplicated in some 15q24 microdeletion syndrome patients [53][54]. Furthermore, PMCA2 was identified by GWAS studies to be associated with ASD [55]. A study which included 717 children associated the cortical morphology, such as cortical thickness and surface area, with autistic traits [56]. Interestingly, a single-nucleotide polymorphism in NPTN was found to be associated with cortical thickness [57]. Furthermore, the paths to ASDs may involve unbalanced excitatory–inhibitory synaptic transmission and abnormal synaptogenesis [58]. Several studies have observed an imbalance of excitatory-inhibitory transmission and altered synaptogenesis in different Nptn-deficient mice [59][60][61][62][63]. In addition, neuroplastin-deficient mice displayed altered social interactions avoiding unfamiliar mice [51]. In conclusion, genetic association studies suggest a link of neuroplastin to autism spectrum disorder, but the role of NPTN in ASD still needs to be specifically addressed. It remains to be seen whether a direct malfunction or loss of neuroplastin, rather than an indirect effect, e.g., via PMCAs, contributes to ASD.

2.2. Depression and Anxiety Disorder

Depression and anxiety are the most common mental disorders in society today, and both frequently co-occur in patients [64][65]. Etiological factors related to depression and anxiety disorder could be linked to childhood trauma, environmental adversity, as well as stressful life events [66]. Furthermore, several genes have been associated with depression and anxiety, among them 5-HTT, NPSR1, and RGS2 [66]. Genetic inactivation of Nptn results in elevated corticosterone levels and increased depressive-like behavior, but reduced anxiety-related behaviors in mice [51]. Mice that lacked only Np65 displayed the opposite phenotype, with reduced depressive-like behavior and increased anxiety [61]. In addition, the neuroplastin binding partners GluA1 and GABAA receptor are associated with anxiety disorder and depression.

2.3. Alzheimer’s (AD) Disease

An alteration of neuroplastin expression in AD patients was reported recently [67]. In the early phase of confirmed AD neuropathology, neuroplastin was significantly upregulated in the hippocampus (dentate gyrus, CA2/3 region, and subiculum) without changes in neuron number or tissue volume. Interestingly, patients experiencing a longer duration of AD disease (5–7 years) showed a decreased expression level of neuroplastin compared to patients with a short duration AD (≤4 years), which may indicate a role of neuroplastin in the early phase of AD. The analysis of neuropathological amyloid plaques and neurofibrillary tangles (NFT) showed a negative correlation between neuroplastin expression level and the number of amyloid plaques in the CA1 area and a weak negative correlation between neuroplastin and NFT in CA1, CA2/3, and subiculum. In human brain, both NPTN and PMCAs exhibit similar expression patterns at the transcriptomic level [68]. In comparison to the aging brain, the expression and activity of PMCA in AD patients were reduced, and the AD hallmarks tau and Aβ showed a negative impact on PMCA activity, which may indicate an altered Ca2+ homeostasis in the AD brain [69][70][71]. Alternatively, Ca2+ dys-homeostasis could promote the accumulation of Aβ and phosphorylated tau protein, which result in the neuropathy and brain function deficits in AD patients [70][71][72]. Aβ is produced by the β- and γ-secretase cleavages of the amyloid precursor protein (APP) [73]. The principal β-secretase for generation of Aβ in vivo is the β-site APP cleaving enzyme 1 (BACE1) [73][74]. The use of BACE1-specific inhibitors has been proposed as a potential intervention in AD [75]; however, this approach must be regarded carefully, as BACE1 cleaves numerous substrates. Interestingly, both neuroplastin and basigin were identified as potential BACE1 substrates [76][77]. Although further studies on the cleavage of Np by BACE1 were not conducted, an attractive hypothesis is that increased neuroplastin cleavage by BACE1 could result in the cognitive deficits observed in AD (Figure 2).
Figure 2. Relation of Neuroplastin to Alzheimer’s disease. The Amyloid Precursor Protein (APP) is cleaved aberrantly by β-secretase (BACE1) and γ-secretase resulting in Aβ. Aβ and tau are considered hallmarks of Alzheimer’s disease. Increased intracellular Ca2+ concentrations are associated with cognitive impairment and increases in Aβ and tau. Intracellular Ca2+ can be deposited into or released from mitochondria and ER as intracellular calcium stores. Energy driven extrusion of Ca2+ is mediated by PMCAs. In the absence of neuroplastin, PMCA levels are reduced and intracellular Ca2+ is increased. The hypothetical cleavage of neuroplastin by BACE1 may result in loss of PMCAs and elevated Ca2+ levels.

2.4. Cognition, Antero- and Retrograde Amnesia

A large-scale genetic association study in adolescents associated NPTN with cortical thickness and intellectual ability [57], suggesting a role for NPTN in cognition and learning and memory. Furthermore, NPTN variants were recently related to creativity [78].
In recent years, we have addressed the role of neuroplastin in learning and memory using several mouse mutants. When neuroplastin was missing from only glutamatergic neurons, achieved using an Emx1-promoter driven Cre-recombinase, associative learning was slightly improved. However, the continuity of task execution was affected, suggesting altered striatum-dependent decision making [79]. The complete loss of neuroplastin expression resulted in a complex phenotype, which included the inability to learn associative tasks [51]. The comparison of Nptn-ablation in glutamatergic versus all neurons suggests a particular role of neuroplastin, expressed by gabaergic interneurons for associative learning. When neuroplastin expression was specifically ablated in all types of neurons after a normal development, again, the anterograde memory was not formed for associative tasks [51]. Furthermore, when the associative tasks were first acquired perfectly before neuroplastin ablation, the induced loss of neuroplastin resulted in specific retrograde amnesia for these associative memories but not for spatial memories [51]. Interestingly, the β-blocker propranolol has retrograde amnestic side effects. Therefore, propranolol is applied as off-label use for the treatment of intrusive thoughts associated with post-traumatic stress disorder (PTSD) (for a review, see: [80]). Propranolol also acts as an inhibitor of the PMCAs [81], and thus its amnestic effects may be related to PMCA inhibition. In vivo, the absence of neuroplastin leads to dramatically reduced PMCA levels [79][51], suggesting that the neuroplastin-PMCA assembly may be critical for associative learning and memory. If this hypothesis can be substantiated, it may provide an opportunity to address PTSD and other psychiatric conditions involving intrusive thoughts.

2.5. Other Diseases Related to Neuroplastin

2.5.1. Deafness

Deafness resulting from the loss of neuroplastin function has been studied using Nptn-deficient and neuroplastin mutant mice [52][60][82]. It was proposed that Np55 expression by outer hair cells is required for cochlear amplification [82], and Carrott et al. [60] proposed Np65-driven synaptogenesis by inner hair cells as necessary for hearing. Recently, we showed that neuroplastin expression is essential for hearing during the development of the hearing system, and also for the maintenance of hearing capabilities in adults throughout their life [52]. Neuroplastin is required for PMCA2 targeting and Ca2+ extrusion in cochlear hair cells [52]. Interestingly, PMCA2 loss of function mutations result in deafness in mice and human [83], verifying that the interaction of neuroplastin with PMCA is decisive for Ca2+ extrusion.

2.5.2. Cancer

The first evidence linking NPTN to cancer came from a bioinformatic analysis showing that NPTN was one of 166 genes with an altered expression in colorectal adenomatous polyps [84]. In a study screening for potential tumor antigens from breast cancer patients, neuroplastin was identified and showed strongly increased immunoreactivity in invasive carcinoma tissues [85]. Moreover, over-expression of neuroplastin in a breast-cancer-derived cell line strongly increased tumor growth and angiogenesis, as well as the production of vascular endothelia growth factor (VEGF), suggesting an angiogenic mechanism regulated by VEGF in the aberrant neuroplastin-expressing tumors [85]. Furthermore, the role of neuroplastin and its interaction with S100A8/A9, resulting in the activation of a cascade for lung cancer disseminative progression and aggressive development, has been proposed [86][87].

2.5.3. Various Diseases

Not surprisingly, the widespread expression of neuroplastin in nearly all organs may result in the discovery of further pathological conditions influenced by neuroplastin, e.g., within the immune system [88] or in heart disease [89].


  1. Vos, T.; Abajobir, A.A.; Abbafati, C.; Abbas, K.M.; Abate, K.A.; Abd-Allah, F.; Abdulle, A.M.; Abebo, T.A.; Abera, S.F.; Aboyans, V.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211–1259.
  2. Zablotsky, B.; Black, L.I.; Maenner, M.J.; Schieve, L.A.; Danielson, M.L.; Bitsko, R.H.; Blumberg, S.J.; Kogan, M.D.; Boyle, C.A. Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009–2017. Pediatrics 2019, 144, e20190811.
  3. Maenner, M.J.; Shaw, K.A.; Baio, J.; Washington, A.; Patrick, M.; DiRienzo, M.; Christensen, D.L.; Wiggins, L.D.; Pettygrove, S.; Andrews, J.G.; et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. MMWR Surveill. Summ. 2020, 69, 1–12.
  4. Sloane, P.D.; Zimmerman, S.; Suchindran, C.; Reed, P.; Wang, L.; Boustani, M.; Sudha, S. The public health impact of Alzheimer’s disease, 2000–2050: Potential implication of treatment advances. Annu. Rev. Public Health 2002, 23, 213–231.
  5. Gustavsson, A.; Svensson, M.; Jacobi, F.; Allgulander, C.; Alonso, J.; Beghi, E.; Dodel, R.; Ekman, M.; Faravelli, C.; Fratiglioni, L.; et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21, 718–779.
  6. Chong, H.Y.; Teoh, S.L.; Wu, D.B.; Kotirum, S.; Chiou, C.F.; Chaiyakunapruk, N. Global economic burden of schizophrenia: A systematic review. Neuropsychiatr. Dis. Treat. 2016, 12, 357–373.
  7. Rogge, N.; Janssen, J. The Economic Costs of Autism Spectrum Disorder: A Literature Review. J. Autism Dev. Disord. 2019, 49, 2873–2900.
  8. Baresic, A.; Nash, A.J.; Dahoun, T.; Howes, O.; Lenhard, B. Understanding the genetics of neuropsychiatric disorders: The poten-tial role of genomic regulatory blocks. Mol. Psychiatry 2020, 25, 6–18.
  9. Sakurai, K.; Migita, O.; Toru, M.; Arinami, T. An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia. Mol. Psychiatry 2002, 7, 412–415.
  10. Munafo, M.R.; Attwood, A.S.; Flint, J. Neuregulin 1 genotype and schizophrenia. Schizophr. Bull. 2008, 34, 9–12.
  11. Bernstein, H.G.; Bogerts, B. Neuregulin-1 alpha, the underestimated molecule: Emerging new roles in normal brain function and the pathophysiology of schizophrenia? Genome 2013, 56, 703–704.
  12. Ripke, S.; Neale, B.M.; Corvin, A.; Walters, J.T.R.; Farh, K.; Holmans, P.A.; Lee, P.; Bulik-Sullivan, B.; Collier, D.A.; Huang, H.; et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511, 421–427.
  13. Dennison, C.A.; Legge, S.E.; Pardinas, A.F.; Walters, J.T.R. Genome-wide association studies in schizophrenia: Recent advances, challenges and future perspective. Schizophr. Res. 2020, 217, 4–12.
  14. Jamain, S.; Quach, H.; Betancur, C.; Rastam, M.; Colineaux, C.; Gillberg, I.C.; Soderstrom, H.; Giros, B.; Leboyer, M.; Gillberg, C.; et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 2003, 34, 27–29.
  15. Yan, J.; Oliveira, G.; Coutinho, A.; Yang, C.; Feng, J.; Katz, C.; Sram, J.; Bockholt, A.; Jones, I.R.; Craddock, N.; et al. Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Mol. Psychiatry 2005, 10, 329–332.
  16. Sudhof, T.C. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008, 455, 903–911.
  17. Sun, Y.; Yao, X.; March, M.E.; Meng, X.; Li, J.; Wei, Z.; Sleiman, P.M.A.; Hakonarson, H.; Xia, Q.; Li, J. Target Genes of Autism Risk Loci in Brain Frontal Cortex. Front. Genet. 2019, 10, 707.
  18. Anney, R.J.L.; Ripke, S.; Anttila, V.; J Grove, J.; Holmans, P.; Huang, H.; Klei, L.; Lee, P.H.; Medland, S.E.; Neale, B.; et al. Me-ta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. Mol. Autism 2017, 8, 21.
  19. Hung, A.Y.; Futai, K.; Sala, C.; Valtschanoff, J.G.; Ryu, J.; Woodworth, M.A.; Kidd, F.L.; Sung, C.C.; Miyakawa, T.; Bear, M.F.; et al. Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J. Neurosci. 2008, 28, 1697–1708.
  20. Peca, J.; Feliciano, C.; Ting, J.T.; Wang, W.; Wells, M.F.; Venkatraman, T.N.; Lascola, C.D.; Fu, Z.; Feng, G. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011, 472, 437–442.
  21. Wang, X.; McCoy, P.A.; Rodriguiz, R.M.; Pan, Y.; Je, H.S.; Roberts, A.C.; Kim, C.J.; Berrios, J.; Colvin, J.S.; Bousquet-Moore, D.; et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum. Mol. Genet. 2011, 20, 3093–3108.
  22. Schmeisser, M.J.; Ey, E.; Wegener, S.; Bockmann, J.; Stempel, A.V.; Kuebler, A.; Janssen, A.L.; Udvardi, P.T.; Shiban, E.; Spilker, C.; et al. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature 2012, 486, 256–260.
  23. Won, H.; Lee, H.R.; Gee, H.Y.; Mah, W.; Kim, J.I.; Lee, J.; Ha, S.; Chung, C.; Jung, E.S.; Cho, Y.S.; et al. Autistic-like social behav-iour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012, 486, 261–265.
  24. Wang, X.; Christian, K.M.; Song, H.; Ming, G.L. Synaptic dysfunction in complex psychiatric disorders: From genetics to mecha-nisms. Genome Med. 2018, 10, 9.
  25. Penzes, P.; Buonanno, A.; Passafaro, M.; Sala, C.; Sweet, R.A. Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. J. Neurochem. 2013, 126, 165–182.
  26. Lopatina, O.L.; Malinovskaya, N.A.; Komleva, Y.K.; Gorina, Y.V.; Shuvaev, A.N.; Olovyannikova, R.Y.; Belozor, O.S.; Belova, O.A.; Higashida, H.; Salmina, A.B. Excitation/inhibition imbalance and impaired neurogenesis in neurodevelopmental and neurodegenerative disorders. Rev. Neurosci. 2019, 30, 807–820.
  27. Anderson, R.M.; Hadjichrysanthou, C.; Evans, S.; Wong, M.M. Why do so many clinical trials of therapies for Alzheimer’s disease fail? Lancet 2017, 390, 2327–2329.
  28. Dhillon, S. Aducanumab: First Approval. Drugs 2021, 81, 1437–1443.
  29. Paik, J. Olanzapine/Samidorphan: First Approval. Drugs 2021, 81, 1431–1436.
  30. LeClerc, S.; Easley, D. Pharmacological therapies for autism spectrum disorder: A review. Pharm. Ther. 2015, 40, 389–397.
  31. Baribeau, D.; Anagnostou, E. Novel treatments for autism spectrum disorder based on genomics and systems biology. Pharmacol. Ther. 2021, 107939.
  32. Doherty, J.L.; Owen, M.J. Genomic insights into the overlap between psychiatric disorders: Implications for research and clinical practice. Genome Med. 2014, 6, 29.
  33. Zheng, Z.; Zheng, P.; Zou, X. Association between schizophrenia and autism spectrum disorder: A systematic review and me-ta-analysis. Autism Res. 2018, 11, 1110–1119.
  34. Grant, S.G. Synaptopathies: Diseases of the synaptome. Curr. Opin. Neurobiol. 2012, 22, 522–529.
  35. Brose, N.; O’Connor, V.; Skehel, P. Synaptopathy: Dysfunction of synaptic function? Biochem. Soc. Trans. 2010, 38, 443–444.
  36. Eltokhi, A.; Janmaat, I.E.; Genedi, M.; Haarman, B.C.M.; Sommer, I.E.C. Dysregulation of synaptic pruning as a possible link between intestinal microbiota dysbiosis and neuropsychiatric disorders. J. Neurosci. Res. 2020, 98, 1335–1369.
  37. Courchesne, E.; Carper, R.; Akshoomoff, N. Evidence of brain overgrowth in the first year of life in autism. JAMA 2003, 290, 337–344.
  38. Walker, L.; Gozzi, M.; Lenroot, R.; Thurm, A.; Behseta, B.; Swedo, S.; Pierpaoli, C. Diffusion tensor imaging in young children with autism: Biological effects and potential confounds. Biol. Psychiatry 2012, 72, 1043–1051.
  39. Tang, G.; Gudsnuk, K.; Kuo, S.H.; Cotrina, M.L.; Rosoklija, G.; Sosunov, A.; Sonders, M.S.; Kanter, E.; Castagna, C.; Yamamoto, A.; et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 2014, 83, 1131–1143.
  40. Belmonte, M.K.; Allen, G.; Beckel-Mitchener, A.; Boulanger, L.M.; Carper, R.A.; Webb, S.J. Autism and abnormal development of brain connectivity. J. Neurosci. 2004, 24, 9228–9231.
  41. Schumann, C.M.; Bloss, C.S.; Barnes, C.C.; Wideman, G.M.; Carper, R.A.; Akshoomoff, N.; Pierce, K.; Hagler, D.; Schork, N.; Lord, C.; et al. Longitudinal magnetic resonance imaging study of cortical development through early childhood in autism. J. Neurosci. 2010, 30, 4419–4427.
  42. Gogtay, N. Cortical brain development in schizophrenia: Insights from neuroimaging studies in childhood-onset schizophrenia. Schizophr. Bull. 2008, 34, 30–36.
  43. Keshavan, M.S.; Anderson, S.; Pettegrew, J.W. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J. Psychiatr. 1994, 28, 239–265.
  44. Mallya, A.P.; Deutch, A.Y. (Micro)Glia as Effectors of Cortical Volume Loss in Schizophrenia. Schizophr. Bull. 2018, 44, 948–957.
  45. Sellgren, C.M.; Gracias, J.; Watmuff, B.; Biag, J.D.; Thanos, J.M.; Whittredge, P.B.; Fu, T.; Worringer, K.; Brown, H.E.; Wang, J.; et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat. Neurosci. 2019, 22, 374–385.
  46. Ouchi, Y.; Kubota, Y.; Kuramasu, A.; Watanabe, T.; Ito, C. Gene expression profiling in whole cerebral cortices of phencyclidine- or methamphetamine-treated rats. Mol. Brain Res. 2005, 140, 142–149.
  47. Sato, M.; Chen, C.C.; Akiyama, K.; Otsuki, S. Acute exacerbation of paranoid psychotic state after long-term abstinence in pa-tients with previous methamphetamine psychosis. Biol. Psychiatry 1983, 18, 429–440.
  48. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. J. Psychiatry 1991, 148, 1301–1308.
  49. Saito, A.; Fujikura-Ouchi, Y.; Kuramasu, A.; Shimoda, K.; Akiyama, K.; Matsuoka, H.; Ito, C. Association study of putative pro-moter polymorphisms in the neuroplastin gene and schizophrenia. Neurosci. Lett. 2007, 411, 168–173.
  50. Mena, A.; Ruiz-Salas, J.C.; Puentes, A.; Dorado, I.; Ruiz-Veguilla, M.; De la Casa, L.G. Reduced Prepulse Inhibition as a Biomarker of Schizophrenia. Front. Behav. Neurosci. 2016, 10, 202.
  51. Bhattacharya, S.; Herrera-Molina, R.; Sabanov, V.; Ahmed, T.; Iscru, E.; Stober, F.; Richter, K.; Fischer, K.D.; Angenstein, F.; Gold-schmidt, J.; et al. Genetically Induced Retrograde Amnesia of Associative Memories After Neuroplastin Ablation. Biol. Psy-chiatry 2017, 81, 124–135.
  52. Lin, X.; Brunk, M.G.K.; Yuanxiang, P.; Curran, A.W.; Zhang, E.; Stober, F.; Goldschmidt, J.; Gundelfinger, E.D.; Vollmer, M.; Hap-pel, M.F.K.; et al. Neuroplastin expression is essential for hearing and hair cell PMCA expression. Brain Struct. Funct. 2021, 226, 1533–1551.
  53. Smith, M.; Spence, M.A.; Flodman, P. Nuclear and mitochondrial genome defects in autisms. Ann. N. Y. Acad. Sci. 2009, 1151, 102–132.
  54. Liu, Y.; Zhang, Y.; Zarrei, M.; Dong, R.; Yang, X.; Zhao, D.; Scherer, S.W.; Gai, Z. Refining critical regions in 15q24 microdeletion syndrome pertaining to autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2020, 183, 217–226.
  55. Carayol, J.; Sacco, R.; Tores, F.; Rousseau, F.; Lewin, P.; Hager, J.; Persico, A.M. Converging evidence for an association of ATP2B2 allelic variants with autism in male subjects. Biol. Psychiatry 2011, 70, 880–887.
  56. Blanken, L.M.; Mous, S.E.; Ghassabian, A.; Muetzel, R.L.; Schoemaker, N.K.; El Marroun, H.; van der Lugt, A.; Jaddoe, V.W.; Hof-man, A.; Verhulst, F.C.; et al. Cortical morphology in 6- to 10-year old children with autistic traits: A population-based neuroimaging study. Am. J. Psychiatry 2015, 172, 479–486.
  57. Desrivieres, S.; Lourdusamy, A.; Tao, C.; Toro, R.; Jia, T.; Loth, E.; Medina, L.M.; Kepa, A.; Fernandes, A.; Ruggeri, B.; et al. Single nucleotide polymorphism in the neuroplastin locus associates with cortical thickness and intellectual ability in adolescents. Mol. Psychiatry 2015, 20, 263–274.
  58. Persico, A.M.; Bourgeron, T. Searching for ways out of the autism maze: Genetic, epigenetic and environmental clues. Trends Neurosci. 2006, 29, 349–358.
  59. Herrera-Molina, R.; Sarto-Jackson, I.; Montenegro-Venegas, C.; Heine, M.; Smalla, K.H.; Seidenbecher, C.I.; Beesley, P.W.; Gun-delfinger, E.D.; Montag, D. Structure of excitatory synapses and GABAA receptor localization at inhibitory synapses are regulated by neuroplastin-65. J. Biol. Chem. 2014, 289, 8973–8988.
  60. Carrott, L.; Bowl, M.R.; Aguilar, C.; Johnson, S.L.; Chessum, L.; West, M.; Morse, S.; Dorning, J.; Smart, E.; Hardisty-Hughes, R.; et al. Absence of Neuroplastin-65 Affects Synaptogenesis in Mouse Inner Hair Cells and Causes Profound Hearing Loss. J. Neurosci. 2016, 36, 222–234.
  61. Li, H.; Liu, Y.; Gao, X.; Liu, L.; Amuti, S.; Wu, D.; Jiang, F.; Huang, L.; Wang, G.; Zeng, J.; et al. Neuroplastin 65 modulates anxiety- and depression-like behavior likely through adult hippocampal neurogenesis and central 5-HT activity. FEBS J. 2019, 286, 3401–3415.
  62. Vemula, S.K.; Malci, A.; Junge, L.; Lehmann, A.C.; Rama, R.; Hradsky, J.; Matute, R.A.; Weber, A.; Prigge, M.; Naumann, M.; et al. The Interaction of TRAF6 With Neuroplastin Promotes Spinogenesis During Early Neuronal Development. Front. Cell Dev. Biol. 2020, 8, 579513.
  63. Amuti, S.; Tang, Y.; Wu, S.; Liu, L.; Huang, L.; Zhang, H.; Li, H.; Jiang, F.; Wang, G.; Liu, X.; et al. Neuroplastin 65 mediates cogni-tive functions via excitatory/inhibitory synapse imbalance and ERK signal pathway. Neurobiol. Learn. Mem. 2016, 127, 72–83.
  64. Diefenbach, G.J.; McCarthy-Larzelere, M.E.; Williamson, D.A.; Mathews, A.; Manguno-Mire, G.M.; Bentz, B.G. Anxiety, depres-sion, and the content of worries. Depress. Anxiety 2001, 14, 247–250.
  65. Tiller, J.W. Depression and anxiety. Med. J. Aust. 2013, 199, S28–S31.
  66. Gottschalk, M.G.; Domschke, K. Genetics of generalized anxiety disorder and related traits. Dialogues Clin. Neurosci. 2017, 19, 159–168.
  67. Ilic, K.; Mlinac-Jerkovic, K.; Jovanov-Milosevic, N.; Simic, G.; Habek, N.; Bogdanovic, N.; Kalanj-Bognar, S. Hippocampal expres-sion of cell-adhesion glycoprotein neuroplastin is altered in Alzheimer’s disease. J. Cell. Mol. Med. 2019, 23, 1602–1607.
  68. Ilic, K.; Mlinac-Jerkovic, K.; Sedmak, G.; Rosenzweig, I.; Kalanj-Bognar, S. Neuroplastin in human cognition: Review of literature and future perspectives. Transl. Psychiatry 2021, 11, 394.
  69. Berrocal, M.; Marcos, D.; Sepulveda, M.R.; Perez, M.; Avila, J.; Mata, A.M. Altered Ca2+ dependence of synaptosomal plasma membrane Ca2+-ATPase in human brain affected by Alzheimer’s disease. FASEB J. 2009, 23, 1826–1834.
  70. Mark, R.J.; Hensley, K.; Butterfield, D.A.; Mattson, M.P. Amyloid beta-peptide impairs ion-motive ATPase activities: Evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. 1995, 15, 6239–6249.
  71. Berrocal, M.; Corbacho, I.; Vazquez-Hernandez, M.; Avila, J.; Sepulveda, M.R.; Mata, A.M. Inhibition of PMCA activity by tau as a function of aging and Alzheimer’s neuropathology. Biochim. Biophys. Acta 2015, 1852, 1465–1476.
  72. Arancio, A.; Ilya, B.; Berger, T.; Bouteiller, J.M.; Carrillo, M.; Disterhoft, J.; Foskett, K.; Khachaturian, A.S.; LaFerla, F.; Landfield, P.W.; et al. Calcium Hypothesis of Alzheimer’s disease and brain aging: A framework for integrating new evidence into a com-prehensive theory of pathogenesis. Alzheimers Dement. 2017, 13, 178–182.e117.
  73. Chen, G.F.; Xu, T.H.; Yan, Y.; Zhou, Y.R.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharm. Sin. 2017, 38, 1205–1235.
  74. Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B.D.; Babu-Khan, S.; Denis, P.; Fan, W.; Kha, H.; Zhang, J.; Gong, Y.; et al. Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 2001, 4, 231–232.
  75. Das, B.; Yan, R. A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment. CNS Drugs 2019, 33, 251–263.
  76. Johnson, J.L.; Chambers, E.; Jayasundera, K. Application of a Bioinformatics-Based Approach to Identify Novel Putative in vivo BACE1 Substrates. Biomed. Eng. Comput. Biol. 2013, 5, 1–15.
  77. Panza, F.; Lozupone, M.; Solfrizzi, V.; Sardone, R.; Piccininni, C.; Dibello, V.; Stallone, R.; Giannelli, G.; Bellomo, A.; Greco, A.; et al. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert Rev. Neurother. 2018, 18, 847–857.
  78. Orwig, W.; Diez, I.; Bueicheku, E.; Vannini, P.; Beaty, R.; Sepulcre, J. Cortical Networks of Creative Ability Trace Gene Expression Profiles of Synaptic Plasticity in the Human Brain. Front. Hum. Neurosci 2021, 15, 694274.
  79. Herrera-Molina, R.; Mlinac-Jerkovic, K.; Ilic, K.; Stober, F.; Vemula, S.K.; Sandoval, M.; Milosevic, N.J.; Simic, G.; Smalla, K.H.; Goldschmidt, J.; et al. Neuroplastin deletion in glutamatergic neurons impairs selective brain functions and calcium regula-tion: Implication for cognitive deterioration. Sci. Rep. 2017, 7, 7273.
  80. Young, C.; Butcher, R. Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness; CADTH Rapid Response Re-ports; Canadian Agency for Drugs and Technologies in Health: Ottawa, ON, Canada, 2020.
  81. Roed, A.; Brodal, B. Inhibition of sarcolemma ATPases by some membrane-stabilizing drugs. Acta Pharm. Toxicol. 1981, 48, 65–68.
  82. Zeng, W.Z.; Grillet, N.; Dewey, J.B.; Trouillet, A.; Krey, J.F.; Barr-Gillespie, P.G.; Oghalai, J.S.; Muller, U. Neuroplastin Isoform Np55 Is Expressed in the Stereocilia of Outer Hair Cells and Required for Normal Outer Hair Cell Function. J. Neurosci. 2016, 36, 9201–9216.
  83. Bortolozzi, M.; Mammano, F. PMCA2 pump mutations and hereditary deafness. Neurosci. Lett. 2018, 663, 18–24.
  84. Gaspar, C.; Cardoso, J.; Franken, P.; Molenaar, L.; Morreau, H.; Moslein, G.; Sampson, J.; Boer, J.M.; de Menezes, R.X.; Fodde, R. Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am. J. Pathol. 2008, 172, 1363–1380.
  85. Rodriguez-Pinto, D.; Sparkowski, J.; Keough, M.P.; Phoenix, K.N.; Vumbaca, F.; Han, D.K.; Gundelfinger, E.D.; Beesley, P.; Claffey, K.P. Identification of novel tumor antigens with patient-derived immune-selected antibodies. Cancer Immunol. Im-munother. 2009, 58, 221–234.
  86. Sumardika, I.W.; Chen, Y.; Tomonobu, N.; Kinoshita, R.; Ruma, I.M.W.; Sato, H.; Kondo, E.; Inoue, Y.; Yamauchi, A.; Murata, H.; et al. Neuroplastin-beta mediates S100A8/A9-induced lung cancer dissminative progression. Mol. Carcinog. 2019, 58, 980–995.
  87. Bajkowska, K.; Sumardika, I.W.; Tomonobu, N.; Chen, Y.; Yamamoto, K.I.; Kinoshita, R.; Murata, H.; Gede Yoni Komalasari, N.L.; Jiang, F.; Yamauchi, A.; et al. Neuroplastin beta-mediated upregulation of solute carrier family 22 member 18 antisense (SLC22A18AS) plays a crucial role in the epithelial-mesenchymal transition, leading to lung cancer cells’ enhanced motility. Biochem. Biophys. Rep. 2020, 22, 100768.
  88. Korthals, M.; Langnaese, K.; Smalla, K.H.; Kahne, T.; Herrera-Molina, R.; Handschuh, J.; Lehmann, A.C.; Mamula, D.; Naumann, M.; Seidenbecher, C.; et al. A complex of Neuroplastin and Plasma Membrane Ca(2+) ATPase controls T cell activation. Sci. Rep. 2017, 7, 8358.
  89. Choy, M.K.; Javierre, B.M.; Williams, S.G.; Baross, S.L.; Liu, Y.; Wingett, S.W.; Akbarov, A.; Wallace, C.; Freire-Pritchett, P.; Rugg-Gunn, P.J.; et al. Promoter interactome of human embryonic stem cell-derived cardiomyocytes connects GWAS re-gions to cardiac gene networks. Nat. Commun. 2018, 9, 2526.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 337
Revisions: 2 times (View History)
Update Date: 28 Sep 2021
Video Production Service